US FDA Fees To Spike In FY 2018, But Small Firms Get Breaks
Executive Summary
The standard US FDA fee for a 510(k) submission will increase 124% in FY 2018, but small companies will see a much more moderate 12% jump. Other fees will increase by between 30%-40% in the coming fiscal year. And, perhaps, the biggest change will be for de novo submissions, which will have a user fee for the first time. FDA issued its inflation-adjusted user-fee schedule following the recent enactment of MDUFA IV.
You may also be interested in...
Most Premarket Applications Will See 7% Increase Next Year
The US FDA has bumped up the cost of filing for a premarket application in fiscal year 2021 by roughly 7%. That’s slightly higher than the user fee increases under MDUFA IV last year.
Medtech Firms To See Significant User Fee Increases In FY 2020
Most categories of medical device user fee applications will be 6% more expensive starting in October. Establishment registration fees will see more than a 7% increase as well, regardless of whether a company is considered a small business.
Third-Party Review: FDA Seeks Tangible 510(k) Results Over Next Three Years
Under a new plan and draft guidance issued by US FDA, the agency is hoping to streamline and improve its third-party review program. The goal is to spend substantially less FDA resources re-reviewing low-to-moderate risk 510(k) applications that go through the program and allow products to enter market sooner.